Mark T. Wagner
Directeur/Membre du Conseil chez Minnetronix Medical, Inc.
Profil
Mark T.
Wagner was the founder of Orasi Medical, Inc. founded in 2007, where he held the title of Chairman from 2007 to 2012.
He currently holds the position of Director at Minnetronix Medical, Inc. since 2015, Director at Sonex Health LLC, and Director at Prenosis, Inc. since 2022.
Mr. Wagner's former positions include Chairman & Chief Executive Officer at SurVivaLink Corp.
from 1996 to 2001, President, Chief Executive Officer & Director at Celleration, Inc. from 2009 to 2015, Chairman & Chief Executive Officer at Altiva Corp., Chief Executive Officer at Provation Software, Inc. from 2001 to 2006, Chairman at VitalMedix, Inc., Director at Endocardial Solutions, Inc., Director at BioMedix, Inc., Independent Director at Miromatrix Medical, Inc. from 2017 to 2021, Independent Director at Alliqua BioMedical, Inc., and VP & General Manager-Global Sleep Solutions Group at Nellcor Puritan Bennett, Inc. from 1993 to 1996.
Mr. Wagner received his undergraduate degree from the University of Southern California in 1978.
Postes actifs de Mark T. Wagner
| Sociétés | Poste | Début |
|---|---|---|
Minnetronix Medical, Inc.
 Minnetronix Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Minnetronix Medical, Inc. provides design, development, manufacturing, commercialization services to the electronics-based medical device and life science marketplaces. The company was founded in 1996 and is headquartered in St. Paul, MN. | Directeur/Membre du Conseil | 05/10/2015 |
Sonex Health LLC
 Sonex Health LLC Medical SpecialtiesHealth Technology Sonex Health LLC develops and manufactures surgical device designed to minimize surgical trauma for carpal tunnel release patients. The company was founded by Darryl Bares, Jay Smith and Aaron Keenan in 2014 and is headquartered in Eagan, MN. | Directeur/Membre du Conseil | - |
Prenosis, Inc.
 Prenosis, Inc. Packaged SoftwareTechnology Services The American company is devoted to ushering in a new era of precision medicine in acute care. Prenosis' immunix™ precision diagnostics and evidence generation platform leverages machine learning algorithms trained on deep biological data and broad clinical data designed to capture and illuminate the complex health states of patients more holistically. The company's proprietary dataset is one of the largest and fastest-growing hybrid biomarker-clinical datasets for sepsis care. Prenosis enables physicians, providers, payers, and pharma to understand patients' unique biology and see people differently. The company was founded by Bobby Reddy and Rashid Bashir, and Bobby Reddy has been the CEO since incorporation. | Directeur/Membre du Conseil | 05/10/2022 |
Anciens postes connus de Mark T. Wagner
| Sociétés | Poste | Fin |
|---|---|---|
| MIROMATRIX MEDICAL INC. | Directeur/Membre du Conseil | 28/06/2021 |
Celleration, Inc.
 Celleration, Inc. Medical SpecialtiesHealth Technology Celleration, Inc. manufactured medical devices. It developed and marketed a proprietary technology to accelerate healing in wounds by delivering therapeutic, low frequency ultrasound without direct contact of the delivery device to the wound surface. The firm’s core product was the MIST Therapy System, impacted all critical aspects of the wound healing process providing clinical and economic benefits to institutions treating nonresponding wounds. The company was founded by Gene Berghoff, Dennis L. Davey and Eliaz P. Babaev in 1999 and was headquartered in Eden Prairie, MN. | Directeur Général | 01/05/2015 |
Orasi Medical, Inc.
 Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Fondateur | 18/08/2012 |
VitalMedix, Inc.
 VitalMedix, Inc. BiotechnologyHealth Technology VitalMedix, Inc., is a Minneapolis-based, development-stage company that has developed a proprietary, rapidly deployable formulation called Tamiasyn that will potentially allow the human body to endure severe blood loss for an extended period of time and also inhibit human organ damage during the resuscitation process. VitalMedix intends to market Tamiasyn in combination with a hemorrhagic shock treatment system named O2Rescue. It is hoped that this system will offer first responders, trauma center surgeons and military medics a simple, safe and reliable product for preventing serious organ damage and death among victims of severe blood loss. It is believed that Tamiasyn might also have potential applications during invasive surgery and organ preservation, and in cases of stroke. Since 2005, the research conducted by VitalMedix has been funded by the Defense Advanced Research Projects Agency (DARPA). Much of this research has been conducted at the University of Minnesota, which is a shareholder in VitalMedix, Inc. The company now holds an exclusive, global license from the University of Minnesota for Tamiasyn. In order for human trials to begin, the Company will need to have an approved Investigational New Drug [IND] application on file with FDA. The IND provides a compilation of all R&D conducted to date including formulation development, animal pharmacology and toxicology, and supportive literature. The IND must also include a plan for intended additional animal studies and clinical trials. Typically, the time to market for a viable drug candidate is 8-10 years. However, manufacturers can request 'fast track' designation for their product and indication for use if the product offers potential as a life-saving technology superior to current therapies. If designated, FDA will work closely with the manufacturer and provide expedited review and approval times if appropriate. VitalMedix, Inc. intends to request fast track status for Tamiasyn in hemorrhagic shock. | Président | 25/02/2010 |
Provation Software, Inc.
 Provation Software, Inc. Packaged SoftwareTechnology Services ProVation Medical, Inc. engages in provision of clinical decision support and procedure documentation solutions. Its products include Provation Apex, Provation MD, Provation Order Sets, Provation Care Plans, and Provation MultiCaregiver. The company was founded by Sean Benson and Daniel Steinberger in 1994 and is headquartered in Minneapolis, MN. | Directeur Général | 01/03/2006 |
Formation de Mark T. Wagner
| University of Southern California | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MIROMATRIX MEDICAL INC. | Health Technology |
| Entreprise privées | 14 |
|---|---|
Endocardial Solutions, Inc.
 Endocardial Solutions, Inc. Medical SpecialtiesHealth Technology Endocardial Solutions, Inc. designs, develops and manufactures a minimally invasive diagnostic system that diagnoses within the span of a few heartbeats, arrhythmia, a potentially fatal abnormal heart rhythm. The company's EnSite catheters and clinical workstations produce a high-resolution, real-time, three-dimensional color display of electrical activity in the heart chamber, thus allowing electrophysiologists to locate and diagnose tachycardia in real-time and to determine the course of treatment. It was founded in 1992. The company is located in St. Paul, MN. | Health Technology |
Altiva Corp.
 Altiva Corp. Electronic Equipment/InstrumentsElectronic Technology Altiva Corp. manufactures and distributes spinal medical devices. Its spinal pathologies products help in treating deformities, degenerative conditions, trauma, and tumors which can result in severe back pain and sometimes paralysis. The company was founded in 1996 and is headquartered in Charlotte, NC. | Electronic Technology |
Orasi Medical, Inc.
Orasi Medical, Inc. Medical/Nursing ServicesHealth Services Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD). | Health Services |
BioMedix, Inc.
 BioMedix, Inc. Medical SpecialtiesHealth Technology BioMedix, Inc. provides equipment and services for non invasive detection of peripheral vascular disease. It provides suite of hardware, software and online services designed to cost-effectively detect peripheral arterial disease. The company was founded by Claver Bundac and Richard C. Magnuson in 1997 and is headquartered in St. Paul, MI. | Health Technology |
Provation Software, Inc.
Provation Software, Inc. Packaged SoftwareTechnology Services ProVation Medical, Inc. engages in provision of clinical decision support and procedure documentation solutions. Its products include Provation Apex, Provation MD, Provation Order Sets, Provation Care Plans, and Provation MultiCaregiver. The company was founded by Sean Benson and Daniel Steinberger in 1994 and is headquartered in Minneapolis, MN. | Technology Services |
SurVivaLink Corp.
 SurVivaLink Corp. Medical SpecialtiesHealth Technology SurVivaLink Corp. designs and manufactures automated external defibrillators used to treat victims of sudden cardiac arrest. The company was founded by Byron L. Gilman on May 24, 1996 and is headquartered in Minneapolis, MN. | Health Technology |
Nellcor Puritan Bennett, Inc.
 Nellcor Puritan Bennett, Inc. Medical SpecialtiesHealth Technology Part of Medtronic Plc, Nellcor Puritan Bennett, Inc. is a company that manufactures and supplies respiratory care products. The company is based in Pleasanton, CA. Nellcor Puritan Bennett was acquired by Mallinckrodt, Inc.(Old) on August 26, 1997 for $1,805.05 million. | Health Technology |
GE Healthcare Ltd. (United Kingdom)
 GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom. | Health Technology |
VitalMedix, Inc.
VitalMedix, Inc. BiotechnologyHealth Technology VitalMedix, Inc., is a Minneapolis-based, development-stage company that has developed a proprietary, rapidly deployable formulation called Tamiasyn that will potentially allow the human body to endure severe blood loss for an extended period of time and also inhibit human organ damage during the resuscitation process. VitalMedix intends to market Tamiasyn in combination with a hemorrhagic shock treatment system named O2Rescue. It is hoped that this system will offer first responders, trauma center surgeons and military medics a simple, safe and reliable product for preventing serious organ damage and death among victims of severe blood loss. It is believed that Tamiasyn might also have potential applications during invasive surgery and organ preservation, and in cases of stroke. Since 2005, the research conducted by VitalMedix has been funded by the Defense Advanced Research Projects Agency (DARPA). Much of this research has been conducted at the University of Minnesota, which is a shareholder in VitalMedix, Inc. The company now holds an exclusive, global license from the University of Minnesota for Tamiasyn. In order for human trials to begin, the Company will need to have an approved Investigational New Drug [IND] application on file with FDA. The IND provides a compilation of all R&D conducted to date including formulation development, animal pharmacology and toxicology, and supportive literature. The IND must also include a plan for intended additional animal studies and clinical trials. Typically, the time to market for a viable drug candidate is 8-10 years. However, manufacturers can request 'fast track' designation for their product and indication for use if the product offers potential as a life-saving technology superior to current therapies. If designated, FDA will work closely with the manufacturer and provide expedited review and approval times if appropriate. VitalMedix, Inc. intends to request fast track status for Tamiasyn in hemorrhagic shock. | Health Technology |
Celleration, Inc.
Celleration, Inc. Medical SpecialtiesHealth Technology Celleration, Inc. manufactured medical devices. It developed and marketed a proprietary technology to accelerate healing in wounds by delivering therapeutic, low frequency ultrasound without direct contact of the delivery device to the wound surface. The firm’s core product was the MIST Therapy System, impacted all critical aspects of the wound healing process providing clinical and economic benefits to institutions treating nonresponding wounds. The company was founded by Gene Berghoff, Dennis L. Davey and Eliaz P. Babaev in 1999 and was headquartered in Eden Prairie, MN. | Health Technology |
Alliqua BioMedical, Inc.
 Alliqua BioMedical, Inc. BiotechnologyHealth Technology Alliqua BioMedical, Inc. engages in commercializing differentiated regenerative medical products which assist the body in the repair or replacement of soft tissue. Its commercial wound care portfolio consists of wound bed preparation and human biologics. It also manufactures custom electron beam cross-linked and aqueous polymer hydrogels used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was founded on October 27, 1997 and is headquartered in Langhorne, PA. | Health Technology |
Minnetronix Medical, Inc.
Minnetronix Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Minnetronix Medical, Inc. provides design, development, manufacturing, commercialization services to the electronics-based medical device and life science marketplaces. The company was founded in 1996 and is headquartered in St. Paul, MN. | Electronic Technology |
Sonex Health LLC
Sonex Health LLC Medical SpecialtiesHealth Technology Sonex Health LLC develops and manufactures surgical device designed to minimize surgical trauma for carpal tunnel release patients. The company was founded by Darryl Bares, Jay Smith and Aaron Keenan in 2014 and is headquartered in Eagan, MN. | Health Technology |
Prenosis, Inc.
Prenosis, Inc. Packaged SoftwareTechnology Services The American company is devoted to ushering in a new era of precision medicine in acute care. Prenosis' immunix™ precision diagnostics and evidence generation platform leverages machine learning algorithms trained on deep biological data and broad clinical data designed to capture and illuminate the complex health states of patients more holistically. The company's proprietary dataset is one of the largest and fastest-growing hybrid biomarker-clinical datasets for sepsis care. Prenosis enables physicians, providers, payers, and pharma to understand patients' unique biology and see people differently. The company was founded by Bobby Reddy and Rashid Bashir, and Bobby Reddy has been the CEO since incorporation. | Technology Services |
